Abstract

Due its ability to provide a global snapshot of kidney physiology, urine has emerged as a highly promising, non-invasive source in the search for new molecular indicators of disease diagnosis, prognosis, and surveillance. In particular, proteomics represents an ideal strategy for the identification of urinary protein markers; thus, a urinomic approach could also represent a powerful tool in the investigation of the most common kidney cancer, which is clear cell Renal Cell Carcinoma (ccRCC). Currently, these tumors are classified after surgical removal using the TNM and nuclear grading systems and prognosis is usually predicted based upon staging. However, the aggressiveness and clinical outcomes of ccRCC remain heterogeneous within each stratified group, highlighting the need for novel molecular indicators that can predict the progression of these tumors. In our study, we explored the association between the urinary proteome and the ccRCC staging and grading classification. The urine proteome of 44 ccRCC patients with lesions of varying severity was analyzed via label-free proteomics. MS data revealed several proteins with altered abundance according to clinicopathological stratification. Specifically, we determined a panel of dysregulated proteins strictly related to stage and grade, suggesting the potential utility of MS-based urinomics as a complementary tool in the staging process of ccRCC.

Highlights

  • Renal Cell Carcinoma (RCC) comprises a heterogeneous group of tumors of which the most frequent (70–80%) and aggressive morphotype is clear cell RCC [1,2]

  • Urine samples were collected from 44 patients (26 males, 18 females; median age at diagnosis of 66 and 69 years, respectively, and mean tumor mass of 5.54 ± 3.33 cm) with a proven diagnosis of clear cell RCC (ccRCC) (Table 1 and Table S1)

  • Specific focus was given to both grade (Low Grade (LG) = G1 and G2; High Grade (HG) = G3 and G4) and stage values in order to evaluate proteomic signatures of different lesions, using a liquid biopsy investigation-based approach

Read more

Summary

Introduction

Renal Cell Carcinoma (RCC) comprises a heterogeneous group of tumors of which the most frequent (70–80%) and aggressive morphotype is clear cell RCC (ccRCC) [1,2]. The other is the grade feature, assessed using the nuclear grading system, which is based primarily on the cytological and morphological description of nucleoli by microscope observation. This system was proposed at the 2013 International Society of Urological Pathology (ISUP) conference and accepted by the WHO in 2016 [7], replacing the previously used Fuhrman grading system [8]. Tumor staging and histological grading classifications are recognized as the main parameters for ccRCC prognosis and are widely used in clinical practice

Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.